Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Peregrine Capital Management LLC

Peregrine Capital Management LLC raised its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.7% during the second quarter, Holdings Channel reports. The firm owned 148,813 shares of the biopharmaceutical company’s stock after purchasing an additional 29,474 shares during the period. Peregrine Capital Management LLC’s holdings in Ultragenyx Pharmaceutical were worth $6,116,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth $28,000. UMB Bank n.a. increased its position in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 352 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Ultragenyx Pharmaceutical by 622.3% in the 1st quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 865 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Ultragenyx Pharmaceutical by 34.0% in the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 400 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 3,182.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 1,623 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

RARE has been the subject of several research reports. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Stifel Nicolaus boosted their price target on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a research report on Friday, May 31st. The Goldman Sachs Group boosted their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company boosted their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald boosted their target price on shares of Ultragenyx Pharmaceutical from $115.00 to $116.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.43.

Ultragenyx Pharmaceutical Trading Down 0.3 %

NASDAQ:RARE traded down $0.18 during trading hours on Friday, hitting $56.78. 754,442 shares of the company traded hands, compared to its average volume of 805,332. The stock has a market capitalization of $4.72 billion, a price-to-earnings ratio of -7.07 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a twelve month low of $31.52 and a twelve month high of $58.73. The firm has a 50-day moving average of $47.29 and a 200 day moving average of $45.70.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company had revenue of $147.03 million during the quarter, compared to analysts’ expectations of $123.20 million. During the same quarter in the prior year, the company posted ($2.25) EPS. The business’s revenue was up 35.7% on a year-over-year basis. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the sale, the chief executive officer now owns 2,243,985 shares of the company’s stock, valued at approximately $112,580,727.45. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the sale, the chief executive officer now owns 2,243,985 shares of the company’s stock, valued at approximately $112,580,727.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Karah Herdman Parschauer sold 9,806 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the sale, the executive vice president now directly owns 57,981 shares in the company, valued at approximately $2,609,145. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,127 shares of company stock worth $1,539,993. 5.80% of the stock is currently owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.